Nykredit A S Purchases Shares of 107,565 Thermo Fisher Scientific Inc. $TMO

Key Points

• Nykredit A/S acquired 107,565 Thermo Fisher Scientific shares during the second quarter, worth approximately $53.9 million. Institutional investors collectively own 89.23% of the company.
• Thermo Fisher exceeded quarterly expectations, reporting $6.03 EPS and $11.99 billion in revenue, while revenue rose 10.5% year over year. Analysts maintain a “Moderate Buy” consensus, with an average price target of $624.64.
• The stock opened at $650.82, near its 52-week high, while recent analyst actions were mixed and insiders sold about 73,768 shares worth $44.1 million over three months. The company also announced a $0.47 quarterly dividend.

Nykredit A S acquired a new position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 107,565 shares of the medical research company's stock, valued at approximately $53,929,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Tsfg LLC raised its position in Thermo Fisher Scientific by 20.4% in the second quarter. Tsfg LLC now owns 112 shares of the medical research company's stock worth $56,000 after purchasing an additional 19 shares in the last quarter. Renasant Bank raised its holdings in shares of Thermo Fisher Scientific by 1.0% in the second quarter. Renasant Bank now owns 1,934 shares of the medical research company's stock valued at $970,000 after buying an additional 20 shares during the last quarter. TCI Wealth Advisors Inc. lifted its position in Thermo Fisher Scientific by 5.4% during the 1st quarter. TCI Wealth Advisors Inc. now owns 431 shares of the medical research company's stock worth $212,000 after buying an additional 22 shares in the last quarter. Legacy Wealth Managment LLC ID grew its holdings in Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock worth $25,000 after acquiring an additional 22 shares during the last quarter. Finally, Chesapeake Wealth Management increased its position in Thermo Fisher Scientific by 0.6% in the 2nd quarter. Chesapeake Wealth Management now owns 3,725 shares of the medical research company's stock valued at $1,868,000 after acquiring an additional 22 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Trading Down 1.1%

Shares of TMO opened at $650.82 on Friday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $663.57. The firm has a market cap of $240.64 billion, a price-to-earnings ratio of 35.01, a PEG ratio of 2.75 and a beta of 0.85. The business's fifty day moving average is $592.80 and its 200-day moving average is $522.93.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.71 by $0.32. The company had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.Thermo Fisher Scientific's revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter last year, the business posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific's payout ratio is presently 10.11%.

Insider Activity

In other news, VP Lisa Britt sold 11,440 shares of the stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total value of $7,014,092.80. Following the sale, the vice president directly owned 14,784 shares of the company's stock, valued at approximately $9,064,366.08. This represents a 43.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Michael Shafer sold 25,500 shares of the company's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the transaction, the executive vice president directly owned 20,994 shares in the company, valued at approximately $12,596,400. The trade was a 54.85% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 73,768 shares of company stock valued at $44,122,820. 0.33% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

TMO has been the subject of a number of research reports. Citigroup lowered Thermo Fisher Scientific from a "buy" rating to an "underperform" rating in a research report on Wednesday, September 9th. KeyCorp reissued an "overweight" rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Weiss Ratings upgraded Thermo Fisher Scientific from a "hold (c)" rating to a "hold (c+)" rating in a research report on Friday, August 28th. BMO Capital Markets downgraded Thermo Fisher Scientific to a "market perform" rating in a report on Wednesday, September 9th. Finally, Evercore set a $570.00 target price on Thermo Fisher Scientific in a research note on Monday, July 6th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $624.64.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of scientific equipment, laboratory services and analytical technologies. The company serves pharmaceutical and biotechnology companies, clinical laboratories, academic and government institutions, industrial businesses and other research organizations.

Its products and services include laboratory instruments, analytical systems, reagents, consumables, software and related services. Thermo Fisher also provides laboratory supplies and equipment, bioproduction solutions, genetic analysis technologies, clinical diagnostics, specialty diagnostic products and contract research and manufacturing services through its laboratory services businesses.

The company was formed in 2006 through the merger of Thermo Electron Corporation and Fisher Scientific International.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.